Revenue and Operating Performance Trends
Examining Parnax Lab’s consolidated financials from fiscal year ending March 2019 through March 2025 reveals a notable expansion in net sales. The company’s revenue nearly doubled from under ₹110 crores in 2019 to approximately ₹188 crores by March 2025. This growth was particularly pronounced after fiscal 2021, where sales surged from ₹89.52 crores to over ₹160 crores in subsequent years, reflecting a strong recovery and market demand.
Operating profit margins have also improved significantly. The operating profit margin excluding other income rose from 9.4% in 2019 to a robust 14.26% in 2025, indicating enhanced operational efficiency and cost management. Operating profit (PBDIT) increased from ₹10.22 crores in 2019 to ₹28.45 crores in 2025, underscoring the company’s ability to convert higher sales into improved earnings before interest, depreciation, and tax.
Raw material costs and employee expenses have risen in line with revenue growth, but the company has maintained control over other expenses, which have increased moderately. This balance has supported the steady expansion of operating profits.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Profitability and Earnings Recovery
Parnax Lab’s profitability has shown a marked turnaround since fiscal 2020, when the company reported a net loss of nearly ₹3 crores. By March 2021, the loss narrowed to less than ₹0.4 crores, and from 2022 onwards, the company returned to consistent profitability. The consolidated net profit rose steadily to ₹11.52 crores by March 2025.
Correspondingly, earnings per share (EPS) improved from a negative ₹3.42 in 2020 to a positive ₹10.03 in 2025, reflecting the company’s successful efforts to restore shareholder value. The profit after tax margin also recovered from negative territory in 2020 and 2021 to a healthy 6.15% in 2025.
Interest expenses have remained relatively stable, around ₹5.3 crores in recent years, while depreciation charges have increased moderately, consistent with asset growth. Despite these costs, the company’s profit before tax has improved significantly, supporting a stronger bottom line.
Balance Sheet Strength and Asset Growth
On the balance sheet front, Parnax Lab’s shareholder funds have expanded from ₹32.54 crores in 2021 to ₹83.10 crores in 2025, driven by retained earnings and capital infusion. The company’s reserves have more than doubled over this period, signalling improved financial stability.
Total liabilities have remained relatively steady around ₹190 crores in recent years, with total debt peaking at ₹71 crores in 2024 before declining to ₹60.64 crores in 2025. This reduction in debt levels is a positive indicator of deleveraging efforts.
Capital expenditure is evident from the increase in gross block assets from ₹76.14 crores in 2021 to ₹120.48 crores in 2025, supported by rising capital work in progress. Net block values have also increased, reflecting ongoing investments in fixed assets.
Current assets have grown substantially, although net current assets remain negative, indicating a working capital deficit that the company manages through short-term borrowings and trade payables.
Is Parnax Lab your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Cash Flow and Liquidity Overview
Cash flow from operating activities has shown a positive trend, increasing from ₹6 crores in 2021 to ₹32 crores in 2025. This improvement reflects better profitability and working capital management. The company has experienced fluctuations in cash flow from investing activities, with significant outflows in recent years due to capital expenditure.
Financing activities have varied, with a notable outflow of ₹15 crores in 2025, indicating debt repayments or dividend payments. Despite these movements, the company has maintained a stable cash position, with closing cash and cash equivalents remaining modest but consistent.
Overall, Parnax Lab’s historical performance illustrates a successful recovery from earlier losses, steady revenue growth, and improving profitability supported by prudent financial management and investment in assets. While working capital remains an area to monitor, the company’s strengthening balance sheet and positive cash flows provide a solid platform for future expansion.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
